Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension)
Sponsor: Pacira Pharmaceuticals, Inc
A PHASE2 clinical study on Bilateral Knee Osteoarthritis, this trial is completed. The trial is conducted by Pacira Pharmaceuticals, Inc and has accumulated 12 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Feb 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2019 — Jan 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2018 — Apr 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pacira Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .